public companies – Talk Bio

Actionable Insights Powered by AI

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

1 week ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring